Changes to NICE’s cost-effectiveness thresholds confirmed
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
NICE is poised to deliver key commitments in the government’s 10 Year Plan for health and care. We’re delighted by the plan’s endorsement of our role in delivering faster, and fairer access to the best innovations. It will strengthen our position in the system, guided by our core purpose.
Our annual report and accounts summarise our key achievements from April 2024 to March 2025.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
